Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;88(2):429-436.
doi: 10.1111/bcp.14978. Epub 2021 Jul 31.

Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series

Clara Salles Figueiredo  1 , Rodrigo Morel Vieira de Melo  1 , Taina Teixeira Viana  1 , Aline Grimaldi Queiroz de Jesus  2 , Tainara Cerqueira da Silva  2 , Vitor Mamedio da Silva  2 , William Neves de Carvalho  1 , Daniela Nascimento Valame da Silva  2 , Luiz Carlos Santana Passos  1
Affiliations
Free article

Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series

Clara Salles Figueiredo et al. Br J Clin Pharmacol. 2022 Feb.
Free article

Abstract

Chagas cardiomyopathy is the most prevalent non-ischaemic cardiomyopathy in Latin America, with high morbidity and mortality even today. Treatment of these patients is based on the use of medications for heart failure. This study evaluated a case series of patients with Chagas heart disease who used sacubitril/valsartan at a referral hospital for this disease in Brazil. After 6 months, there was a symptomatic improvement in these individuals assessed by the New York Heart Association (NYHA) functional class, with a 44.3% reduction in the absolute number of patients classified as III-IV in the period (P = 0.035), but without changes in the parameters on the echocardiogram for reverse ventricular remodelling. There was a high mortality rate and number of hospitalizations. These results emphasize the importance of studying the use of sacubitril/valsartan in Chagas heart disease to better describe its effectiveness considering the particularities of these individuals.

Keywords: Chagas cardiomyopathy; Chagas disease; heart failure; sacubitril/valsartan.

PubMed Disclaimer

References

REFERENCES

    1. Nunes MCP, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018;138(12):e169-e209. https://doi.org/10.1161/CIR.0000000000000599
    1. Bestetti RB, Otaviano AP, Fantini JP, Cardinalli-Neto A, Nakazone MA, Nogueira PR. Prognosis of patients with chronic systolic heart failure: Chagas disease versus systemic arterial hypertension. Int J Cardiol. 2013;168(3):2990-2991. https://doi.org/10.1016/j.ijcard.2013.04.015
    1. Theodoropoulos TAD, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int J Cardiol. 2008;128(1):22-29. https://doi.org/10.1016/j.ijcard.2007.11.057
    1. Nakazone MA, Otaviano AP, Machado MN, Bestetti RB. Does left ventricular reverse remodeling influence long-term outcomes in patients with Chagas cardiomyopathy? Cardiol J. 2020:1-9. https://doi.org/10.5603/cj.a2020.0038
    1. Botoni FA, Ribeiro ALP, Marinho CC, Lima MMO, Nunes MDCP, Rocha MOC. Treatment of Chagas cardiomyopathy. Biomed Res Int. 2013;2013:1-9. https://doi.org/10.1155/2013/849504

LinkOut - more resources